NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Royalty Pharma PLC RPRX
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY4 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$2.4B
▲ 5.1% vs FY2024
Dividend streak
4 yrs
Raised every year since 2022
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
32.4%
Dividend coverage
2.3×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.4B
Revenue, FY2025 · full 8-year series below
Revenue
Net income
32 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 2.3 times — the rest stayed in the company.
Profitability
—
Return on equity, FY2025
ROE
Operating margin65.6%
Net margin32.4%
Return on assets4.1%
Returned to shareholders
USD 1.2B
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 1.2B
Share of profit159.2%
Consecutive raises4 years
USD 1.2B in buybacks — 159% of the year's profit, so the payout drew on cash built up earlier.
Growth
+2.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.1%
+2.3%
Net income
+162.1%
−4.6%
EPS, diluted
+161.1%
+6.2%
Dividend / share
+7.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 19.6B
total assets, end of FY2025
Total assetsUSD 19.6B
CashUSD 618.7M
Gross debtUSD 9.0B
Net debtUSD 8.3B
Current ratio2.40×
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
2.4
2.3
2.4
2.2
2.3
2.1
1.8
1.8
Operating income $B
1.6
1.3
1.5
0.3
1.4
1.6
2.6
1.4
EBITDA $B
1.6
1.3
1.5
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.8
0.9
1.1
0.0
0.6
1.0
2.3
1.4
EPS, diluted $
·
·
·
·
·
·
·
·
Dividend / sh $
·
0.84
0.80
0.76
0.68
0.30
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
20 of 20
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed